

Curriculum vitae Stefano Landi (09/02/2020)

Courses and education:

- 1981/82 –1985/86: High School (Diploma di Maturità Scientifica)
- 1986/87 –1990/91: Master degree in Biological Sciences. University of Pisa. Final score: 110/110 + laudem
- 1991–1992: Post-lauream training and membership to the professional registry of the biologists
- 1991–1994: Ph D. (1) in Genetics. University of Ferrara

- November 1994 - October 1996: Post-doctoral fellowship
- October 1996 - March 1997: Fellowship (Finnish Institute of Occupational Health, Helsinki, Finland)
- April 1997 - April 1999: Fellowships, University of Pisa
- February 1998 – February 2000: Post-Doctoral position, Associateship Award.
US Environmental Protection Agency (USEPA), Research Triangle Park, North Carolina, USA. Tutor: Dr. David DeMarini.

- February – November 2000: Post-Doctoral position, Special Training Award. International Agency for Research on Cancer (IARC). Tutor: Dr. Federico Canzian
- December 2000 – November 2002: Post-doctoral position, Marie-Curie Individual Fellowship (HPMFCT-2000-00483). IARC, Lione, Francia. Tutor: Dr. Federico Canzian
- November 1999 – July 2001: Ph.D. (2) in Applied Genetics. University of Pisa.
- 1/5/2001 – 1/5/2004: Short-term position as Scientist Researcher. Genetics, University of Pisa
- Since 1/5/2004 – 31/12/2011: Permanent position as Scientist Researcher. Genetics, University of Pisa
- 1/1/2012 – 31/12/2015: Associate professor of Genetics (SSD BIO/18). University of Pisa
- 01/01/2016 – present: Full professor of Genetics (SSD BIO/18). University of Pisa

Research grants:

- 1) Marie-Curie Reintegration Grant, European Commission (MERC-CT-2004-506373)
- 2) Buzzi Unicem Foundation, grant number 180, 2/7/2004
- 3) AIRC- Regional Grants. N. 1082 years 2005-2007, co-investigator
- 4) AIRC- Principal Investigator Grant. N. 1714 years 2005-2006
- 5) NCI (NIH-USA) Grant code R03CA115062, years 2006-2008.
- 6) AIRC- Principal Investigator Grant. N. 4601, years 2008-2011
- 7) Buzzi Unicem Foundation, grant number 156, 25/02/2010 (cod. P22)
- 8) Italian Ministry of Research, PRIN grant 2009-2012

9) 2004-2016. Regular budget, University of Pisa

10) ITT, Tuscany Research Institute of Research on Cancer (2014-2017). Project title: "Variation in miRNA genes and in miRNA binding sites of DNA repair genes as diagnostic, predictive and prognostic factors of colorectal cancer"

11) PRA projects program (University of Pisa). PRA_2016_21, year 2015-2016

12) 05/2017-2020 Fondazione Pisa. Diatec-Meso. PI research grant system.

13) AIRC, Italian Association for Research on Cancer (2019-), 5 years Investigator Grant

Teaching activity:

- Years 2002-2003: "Genetics II" (for the Master degree in Biological Science, University of Pisa, 5 credits).
- Years 2003-2004: "Genetic Engineering" (for the Bachelor degree in Biological and Molecular Biology, University of Pisa, 6 credits).
- Years 2004-2010: "Structural and Functional Genomics" (for the Master degree in Biomolecular sciences and technologies, University of Pisa, 5 credits).
- Years 2009-2016: "Genetics and Genomics analyses" (for the Master degree in Cellular and Molecular Biology, University of Pisa, 6 credits).
- Years 2011-2014: "General Biology" (for the Bachelor degree in Natural Sciences, University of Pisa, 6 credits)
- Years 2015-present: "Genetics" (for the Bachelor degree in Biological Sciences, University of Pisa, 9 credits)
- Year 2016-2018: "Neurogenomics" (for the Master Degree in Neurosciences, University of Pisa, 3 credits)
- Year 2018: "Genetics" (for the Bachelor degree in Biotechnologies, University of Pisa, 6 credits)
- Year 2019- present: "Genetics" (for the Bachelor degree in Natural Sciences, University of Pisa, 6 credits)

Pisa, 15/10/2019



List of publications:

1. Psychiatric disorders and SLC6A4 gene variants: possible effects on alcohol dependence and alzheimer's disease. Calabrò M, Mandelli L, Crisafulli C, Porcelli S, Albani D, Politis A, Papadimitriou GN, Di Nicola M, Janiri L, Colombo R, Martinotti G, Bellomo A, Vieta E, Bonassi S, Frustaci A, Ducci G, Landi S, Boccia S, Serretti A. *Mol Biol Rep*. 2019 Oct 8. doi: 10.1007/s11033-019-05119-5. PMID: 31595439
2. Functional polymorphism within NUP210 encoding for nucleoporin GP210 is associated with the risk of endometriosis. Cipollini M, Luisi S, Piomboni P, Luddi A, Landi D, Melaiu O, Figlioli G, Garritano S, Cappelli V, Viganò P, Gemignani F, Petraglia F, Landi S. *Fertil Steril*. 2019 Aug;112(2):343-352.e1. doi: 10.1016/j.fertnstert.2019.04.011. Epub 2019 Jun 27. PMID: 31256999
3. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Obazee O, Archibugi L, Andriulli A, Soucek P, Malecka-Panas E, Ivanauskas A, Johnson T, Gazouli M, Pausch T, Lawlor RT, Cavestro GM, Milanetto AC, Di Leo M, Pasquali C, Hegyi P, Szentesi A, Radu CE, Gheorghe C, Theodoropoulos GE, Bergmann F, Brenner H, Vodickova L, Katzke V, Campa D, Strobel O, Kaiser J, Pezzilli R, Federici F, Mohelnikova-Duchonova B, Boggi U, Lemstrova R, Johansen JS, Bojesen SE, Chen I, Jensen BV, Capurso G, Puzianza V, Dervenis C, Sperti C, Mambrini A, Hackert T, Kaaks R, Basso D, Talar-Wojnarowska R, Maiello E, Izbicki JR, Cuk K, Saum KU, Cantore M, Kupcinskas J, Palmieri O, Delle Fave G, Landi S, Salvia R, Fogar P, Vashist YK, Scarpa A, Vodicka P, Tjaden C, Iskierka-Jazdzewska E, Canzian F. *Int J Cancer*. 2019 Aug 1;145(3):686-693. doi: 10.1002/ijc.32127. Epub 2019 Feb 7. PMID: 30672594
4. DNA repair and cancer in colon and rectum: Novel players in genetic susceptibility. Pardini B, Corrado A, Paolicchi E, Cugliari G, Berndt SI, Bezieau S, Bien SA, Brenner H, Caan BJ, Campbell PT, Casey G, Chan AT, Chang-Claude J, Cotterchio M, Gala M, Gallinger SJ, Haile RW, Harrison TA, Hayes RB, Hoffmeister M, Hopper JL, Hsu L, Huyghe J, Jenkins MA, Le Marchand L, Lin Y, Lindor NM, Nan H, Newcomb PA, Ogino S, Potter JD, Schoen RE, Slattery ML, White E, Vodickova L, Vymetalkova V, Vodicka P, Gemignani F, Peters U, Naccarati A, Landi S. *Int J Cancer*. 2019 Jun 17. doi: 10.1002/ijc.32516. [Epub ahead of print] PMID: 31209889
5. Genetic basis of psychopathological dimensions shared between schizophrenia and bipolar disorder. Corponi F, Bonassi S, Vieta E, Albani D, Frustaci A, Ducci G, Landi S, Boccia S, Serretti A, Fabbri C. *Prog Neuropsychopharmacol Biol Psychiatry*. 2019 Mar 8;89:23-29. doi: 10.1016/j.pnpbp.2018.08.023. Epub 2018 Aug 24. PMID: 30149091
6. Genetic determinants of telomere length and risk of pancreatic cancer: a PANDORA study. Campa D, Matarazzi M, Greenhalf W, Bijlsma M, Saum KU, Pasquali C, van Laarhoven H, Szentesi A, Federici F, Vodicka P, Funel N, Pezzilli R, Bueno-de-Mesquita HB, Vodickova L, Basso D, Obazee O, Hackert T, Soucek P, Cuk K, Kaiser J, Sperti C, Lovecek M, Capurso G, Mohelnikova-Duchonova B, Khaw KT, König AK, Kupcinskas J, Kaaks R, Bambi F, Archibugi L, Mambrini A, Cavestro GM, Landi S, Hegyi P, Izbicki JR, Gioffreda D, Zambon CF, Tavano F, Talar-Wojnarowska R, Jamrozak K, Key TJ, Fave GD, Strobel O, Jonaitis L, Andriulli A, Lawlor RT, Pirozzi F, Katzke V, Valsuani C, Vashist YK, Brenner H, Canzian F. *Int J Cancer*. 2018 Oct 16. doi: 10.1002/ijc.31928. [Epub ahead of print] PMID: 30325019
7. Correction: Inherited variants in genes somatically mutated in thyroid cancer. Campo C, Köhler A, Figlioli G, Elisei R, Romei C, Cipollini M, Bambi F, Hemminki K, Gemignani F, Landi S, Försti A. *PLoS One*. 2018 Aug 7;13(8):e0202208. doi: 10.1371/journal.pone.0202208. eCollection 2018. PMID: 30086163
8. Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. Obazee O, Capurso G, Tavano F, Archibugi L, De Bonis A, Greenhalf W, Key T, Pasquali C, Milanetto AC, Hackert T, Fogar P, Lico V, Dervenis C, Lawlor RT, Landoni L, Gazouli M, Zambon CF, Funel N, Strobel O, Jamrozak K, Cantu C, Malecka-Panas E, Landi S, Neoptolemos JP, Basso D, Talar-Wojnarowska R, Rinzivillo M, Andriulli A, Canzian F, Campa D. *Carcinogenesis*. 2018 Jul 3;39(7):969. doi: 10.1093/carcin/bgy067. No abstract available. PMID: 29868886
9. The polymorphism rs2480258 within CYP2E1 is associated with different rates of acrylamide metabolism in vivo in humans. Pellè L, Carlsson H, Cipollini M, Bonotti A, Foddìs R, Cristaudo A, Romei C, Elisei R, Gemignani F, Törnqvist M, Landi S. *Arch Toxicol*. 2018 Jun;92(6):2137-2140. doi: 10.1007/s00204-018-2211-2. Epub 2018 May 10. PMID: 29748789
10. Overexpressed genes in malignant pleural mesothelioma: implications in clinical management. Barone E, Gemignani F, Landi S. *J Thorac Dis*. 2018 Jan;10(Suppl 2):S369-S382. doi: 10.21037/jtd.2017.10.158. Review. PMID: 29507807 Free PMC Article
11. Biomarkers in the prevention and follow-up of workers exposed to asbestos. Foddìs R, Bonotti A, Landi S, Fallahi P, Guglielmi G, Cristaudo A. *J Thorac Dis*. 2018 Jan;10(Suppl 2):S360-S368. doi: 10.21037/jtd.2017.12.17. Review. PMID: 29507806 Free PMC Article
12. The genetic susceptibility in the development of malignant pleural mesothelioma. Melaiu O, Gemignani F, Landi S. *J Thorac Dis*. 2018 Jan;10(Suppl 2):S246-S252. doi: 10.21037/jtd.2017.10.41. Review. PMID: 29507792 Free PMC Article
13. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Klein AP, Wolpin BM, Risch HA, Stolzenberg-Solomon RZ, Mucci E, Zhang M, Canzian F, Childs EJ, Hoskins JW, Jermusyk A, Zhong J, Chen F, Albanes D, Andreotti G, Arslan AA, Babic A, Bamlet WR, Beane-Freeman L, Berndt SI, Blackford A, Borges M, Borgida A, Bracci PM, Brais L, Brennan P, Brenner H, Bueno-de-Mesquita B, Buring J, Campa D, Capurso G, Cavestro GM, Chaffee KG, Chung CC, Cleary S, Cotterchio M, Dijk F, Duell EJ, Foretova L, Fuchs C, Funel N, Gallinger S, M Gaziano JM, Gazouli M, Giles GG, Giovannucci E, Goggins M, Goodman GE, Goodman PJ, Hackert T, Haiman C, Hartge P, Hasan M, Hegyi P, Helzlsouer KJ, Herman J, Holcatova I, Holly EA, Hoover R, Hung RJ, Jacobs EJ, Jamrozak K, Janout V, Kaaks R, Khaw KT, Klein EA, Kogevinas M, Kooperberg C, Kulke MH, Kupcinskas J, Kurtz RJ, Laheru D, Landi S, Lawlor RT, Lee IM, LeMarchand L, Lu L, Malats N, Mambrini A, Mannisto S, Milne RL, Mohelniková-Duchoňová B, Neale RE, Neoptolemos JP, Oberg AL, Olson SH, Orlov I, Pasquali C, Patel AV, Peters U, Pezzilli R, Porta M, Real FX, Rothman N, Scelo G, Sesso HD, Severi G, Shu XO, Silverman D, Smith JP, Soucek P, Sund M, Talar-Wojnarowska R, Tavano F, Thornquist MD, Tobias GS, Van Den Eeden SK,

Vashist Y, Visvanathan K, Vodicka P, Wactawski-Wende J, Wang Z, Wentzensen N, White E, Yu H, Yu K, Zeleniuch-Jacquotte A, Zheng W, Kraft P, Li D, Chanock S, Obazee O, Petersen GM, Amundadottir LT. *Nat Commun.* 2018 Feb 8;9(1):556. doi: 10.1038/s41467-018-02942-5. PMID: 29422604 Free PMC Article

14. Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. Obazee O, Capurso G, Tavano F, Archibugi L, De Bonis A, Greenhalf W, Key T, Pasquali C, Milanetto AC, Hackert T, Fogar P, Liço V, Dervenis C, Lawlor RT, Landoni L, Gazouli M, Zambon CF, Funel N, Strobel O, Jamroziak K, Cantù C, Malecka-Panas E, Landi S, Neoptolemos JP, Basso D, Talar-Wojnarowska R, Rinzivillo M, Andriulli A, Canzian F, Campa D. *Carcinogenesis.* 2018 Mar 8;39(3):360-367. doi: 10.1093/carcin/bgx150. PMID: 29309705
15. MicroRNA-binding site polymorphisms in genes involved in colorectal cancer etiopathogenesis and their impact on disease prognosis. Schneiderova M, Naccarati A, Pardini B, Rosa F, Gaetano CD, Jiraskova K, Opattova A, Levy M, Veskrna K, Veskmova V, Buchler T, Landi S, Vodicka P, Vymetalkova V. *Mutagenesis.* 2017 Oct 17;32(5):533-542. doi: 10.1093/mutage/gex026. PMID: 29048575
16. Association between polymorphisms of TAS2R16 and susceptibility to colorectal cancer. Barontini J, Antinucci M, Tofanelli S, Cammalleri M, Dal Monte M, Gemignani F, Vodicka P, Marangoni R, Vodickova L, Kupcinskis J, Vymetalkova V, Forsti A, Canzian F, Stein A, Moreno V, Mastrodonato N, Tavano F, Panza A, Barale R, Landi S, Campa D. *BMC Gastroenterol.* 2017 Sep 15;17(1):104. doi: 10.1186/s12876-017-0659-9. PMID: 28915899 Free PMC Article
17. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Campa D, Pastore M, Capurso G, Hackert T, Di Leo M, Izbicki JR, Khaw KT, Gioffreda D, Kupcinskis J, Pasquali C, Macinga P, Kaaks R, Stigliano S, Peeters PH, Key TJ, Talar-Wojnarowska R, Vodicka P, Valente R, Vashist YK, Salvia R, Papaconstantinou I, Shimizu Y, Valsuani C, Zambon CF, Gazouli M, Valantiene I, Niesen W, Mohelnikova-Duchonova B, Hara K, Soucek P, Malecka-Panas E, Bueno-de-Mesquita HBA, Johnson T, Brenner H, Tavano F, Fogar P, Ito H, Sperti C, Butterbach K, Latiano A, Andriulli A, Cavestro GM, Busch ORC, Dijk F, Greenhalf W, Matsuo K, Lombardo C, Strobel O, König AK, Cuk K, Strothmann H, Katzke V, Cantore M, Mambriani A, Oliverius M, Pezzilli R, Landi S, Canzian F. *Int J Cancer.* 2018 Jan 15;142(2):290-296. doi: 10.1002/ijc.31047. Epub 2017 Oct 16. PMID: 28913878
18. Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDoRA Consortium. Campa D, Obazee O, Pastore M, Panzuto F, Liço V, Greenhalf W, Katzke V, Tavano F, Costello E, Corbo V, Talar-Wojnarowska R, Strobel O, Zambon CF, Neoptolemos JP, Zerboni G, Kaaks R, Key TJ, Lombardo C, Jamroziak K, Gioffreda D, Hackert T, Khaw KT, Landi S, Milanetto AC, Landoni L, Lawlor RT, Bambi F, Pirozzi F, Basso D, Pasquali C, Capurso G, Canzian F. *Cancer Epidemiol Biomarkers Prev.* 2017 Aug;26(8):1349-1351. doi: 10.1158/1055-9965.EPI-17-0075. PMID: 28765340 Free Article
19. Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddìs R, Mutti L, Barale R, Gemignani F, Giamas G, Landi S. *PLoS One.* 2017 Jun 22;12(6):e0180317. doi: 10.1371/journal.pone.0180317. eCollection 2017. PMID: 28640856 Free PMC Article
20. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. De Santi C, Melaiu O, Bonotti A, Cascione L, Di Leva G, Foddìs R, Cristaudo A, Lucchi M, Mora M, Truini A, Tironi A, Murer B, Boldorini R, Cipollini M, Gemignani F, Gasparini P, Mutti L, Landi S. *Sci Rep.* 2017 Jun 9;7(1):3140. doi: 10.1038/s41598-017-02694-0. PMID: 28600498 Free PMC Article
21. Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines. Melaiu O, Catalano C, De Santi C, Cipollini M, Figlioli G, Pellè L, Barone E, Evangelista M, Guazzelli A, Boldrini L, Sensi E, Bonotti A, Foddìs R, Cristaudo A, Mutti L, Fontanini G, Gemignani F, Landi S. *Genes Cancer.* 2017 Jan;8(1-2):438-452. doi: 10.18632/genesandcancer.129. PMID: 28435517 Free PMC Article
22. Inherited variants in genes somatically mutated in thyroid cancer. Campo C, Köhler A, Figlioli G, Elisei R, Romei C, Cipollini M, Bambi F, Hemminki K, Gemignani F, Landi S, Försti A. *PLoS One.* 2017 Apr 14;12(4):e0174995. doi: 10.1371/journal.pone.0174995. eCollection 2017. Erratum in: *PLoS One.* 2018 Aug 7;13(8):e0202208. PMID: 28410400 Free PMC Article
23. A Novel Panel of Serum Biomarkers for MPM Diagnosis. Bonotti A, Foddìs R, Landi S, Melaiu O, De Santi C, Giusti L, Donadio E, Ciregia F, Mazzoni MR, Lucacchini A, Bovenzi M, Comar M, Pantani E, Pistelli A, Cristaudo A. *Dis Markers.* 2017;2017:3510984. doi: 10.1155/2017/3510984. Epub 2017 Feb 28. PMID: 28348450 Free PMC Article
24. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals. De Santi C, Pucci P, Bonotti A, Melaiu O, Cipollini M, Silvestri R, Vymetalkova V, Barone E, Paolicchi E, Corrado A, Lepori I, Dell'Anno I, Pellè L, Vodicka P, Mutti L, Foddìs R, Cristaudo A, Gemignani F, Landi S. *Occup Environ Med.* 2017 Jun;74(6):456-463. doi: 10.1136/oemed-2016-104024. Epub 2017 Mar 25. PMID: 28343162
25. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Mohelnikova-Duchonova B, Strouhal O, Hughes DJ, Holcatova I, Oliverius M, Kala Z, Campa D, Rizzato C, Canzian F, Pezzilli R, Talar-Wojnarowska R, Malecka-Panas E, Sperti C, Federico Zambon C, Pedrazzoli S, Fogar P, Milanetto AC, Capurso G, Delle Fave G, Valente R, Gazouli M, Malleo G, Teresa Lawlor R, Strobel O, Hackert T, Giese N, Vodicka P, Vodickova L, Landi S, Tavano F, Gioffreda D, Piepoli A, Paziienza V, Mambriani A, Pedata M, Cantore M, Bambi F, Ermini S, Funel N, Lemstrova R, Soucek P. *Sci Rep.* 2017 Mar 8;7:43812. doi: 10.1038/srep43812. PMID: 28272475 Free PMC Article

26. Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. Telomeres Mendelian Randomization Collaboration, Haycock PC, Burgess S, Nounu A, Zheng J, Okoli GN, Bowden J, Wade KH, Timpson NJ, Evans DM, Willeit P, Aviv A, Gaunt TR, Hemani G, Mangino M, Ellis HP, Kurian KM, Pooley KA, Eeles RA, Lee JE, Fang S, Chen WV, Law MH, Bowdler LM, Iles MM, Yang Q, Worrall BB, Markus HS, Hung RJ, Amos CI, Spurdle AB, Thompson DJ, O'Mara TA, Wolpin B, Amundadottir L, Stolzenberg-Solomon R, Trichopoulou A, Onland-Moret NC, Lund E, Duell EJ, Canzian F, Severi G, Overvad K, Gunter MJ, Tumino R, Svenson U, van Rij A, Baas AF, Bown MJ, Samani NJ, van t'Hof FNG, Tromp G, Jones GT, Kuivaniemi H, Elmore JR, Johansson M, Mckay J, Scelo G, Carreras-Torres R, Gaborieau V, Brennan P, Bracci PM, Neale RE, Olson SH, Gallinger S, Li D, Petersen GM, Risch HA, Klein AP, Han J, Abnet CC, Freedman ND, Taylor PR, Maris JM, Aben KK, Kiemeny LA, Vermeulen SH, Wiencke JK, Walsh KM, Wrensch M, Rice T, Turnbull C, Litchfield K, Paternoster L, Standl M, Abecasis GR, SanGiovanni JP, Li Y, Mijatovic V, Sapkota Y, Low SK, Zondervan KT, Montgomery GW, Nyholt DR, van Heel DA, Hunt K, Arking DE, Ashar FN, Sotoodehnia N, Woo D, Rosand J, Comeau ME, Brown WM, Silverman EK, Hokanson JE, Cho MH, Hui J, Ferreira MA, Thompson PJ, Morrison AC, Felix JF, Smith NL, Christiano AM, Petukhova L, Betz RC, Fan X, Zhang X, Zhu C, Langefeld CD, Thompson SD, Wang F, Lin X, Schwartz DA, Fingerlin T, Rotter JI, Cotch MF, Jensen RA, Munz M, Dommisch H, Schaefer AS, Han F, Ollila HM, Hillary RP, Albagha O, Ralston SH, Zeng C, Zheng W, Shu XO, Reis A, Uebe S, Hüffmeier U, Kawamura Y, Otowa T, Sasaki T, Hibberd ML, Davila S, Xie G, Siminovich K, Bei JX, Zeng YX, Försti A, Chen B, Landi S, Franke A, Fischer A, Ellinghaus D, Flores C, Noth I, Ma SF, Foo JN, Liu J, Kim JW, Cox DG, Delattre O, Mirabeau O, Skibola CF, Tang CS, Garcia-Barcelo M, Chang KP, Su WH, Chang YS, Martin NG, Gordon S, Wade TD, Lee C, Kubo M, Cha PC, Nakamura Y, Levy D, Kimura M, Hwang SJ, Hunt S, Spector T, Soranzo N, Manichaikul AW, Barr RG, Kahali B, Speliotes E, Yerges-Armstrong LM, Cheng CY, Jonas JB, Wong TY, Fogh I, Lin K, Powell JF, Rice K, Relton CL, Martin RM, Davey Smith G. *JAMA Oncol.* 2017 May 1;3(5):636-651. doi: 10.1001/jamaoncol.2016.5945. PMID: 28241208 Free PMC Article
27. Identification of MiR-21-5p as a Functional Regulator of Mesothelin Expression Using MicroRNA Capture Affinity Coupled with Next Generation Sequencing. De Santi C, Vencken S, Blake J, Haase B, Benes V, Gemignani F, Landi S, Greene CM. *PLoS One.* 2017 Jan 26;12(1):e0170999. doi: 10.1371/journal.pone.0170999. eCollection 2017. PMID: 28125734 Free PMC Article
28. Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors. Campa D, Capurso G, Pastore M, Talar-Wojnarowska R, Milanetto AC, Landoni L, Maiello E, Lawlor RT, Malecka-Panas E, Funel N, Gazouli M, De Bonis A, Klüter H, Rinzivillo M, Delle Fave G, Hackert T, Landi S, Bugert P, Bambi F, Archibugi L, Scarpa A, Katzke V, Dervenis C, Liço V, Furlanello S, Strobel O, Tavano F, Basso D, Kaaks R, Pasquali C, Gentiluomo M, Rizzato C, Canzian F. *Sci Rep.* 2016 Dec 23;6:39565. doi: 10.1038/srep39565. PMID: 28008994 Free PMC Article
29. Bonafide Targets of Deregulated microRNAs in Non-Small Cell Lung Cancer as Tool to Identify Novel Therapeutic Targets: A Review. Cipollini M, Landi S, Gemignani F. *Curr Pharm Des.* 2017;23(1):55-72. doi: 10.2174/1381612822666161006152838. Review. PMID: 27719642
30. Identification of miRSNPs associated with the risk of multiple myeloma. Macaudo A, Calvetti D, Maccari G, Hemminki K, Försti A, Goldschmidt H, Weinhold N, Houlston R, Andersen V, Vogel U, Buda G, Varkonyi J, Sureda A, Martinez Lopez J, Watek M, Butrym A, Sarasquete ME, Dudziński M, Jurczyszyn A, Druzd-Sitek A, Kruszewski M, Subocz E, Petrini M, Iskierka-Jażdżewska E, Rażny M, Szombath G, Marques H, Zawirska D, Chraniuk D, Halka J, Hove Jacobsen SE, Mazur G, García Sanz R, Dumontet C, Moreno V, Stępień A, Beider K, Pelosini M, Manuel Reis R, Krawczyk-Kulis M, Rymko M, Avet-Loiseau H, Lesueur F, Grząśko N, Ostrovsky O, Jamrozik K, Vangsted AJ, Jerez A, Tomczak W, Zaucha JM, Kadar K, Sainz J, Nagler A, Landi S, Gemignani F, Canzian F. *Int J Cancer.* 2017 Feb 1;140(3):526-534. doi: 10.1002/ijc.30465. Epub 2016 Nov 9. PMID: 27718532 Free Article
31. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Zhang M, Wang Z, Obazee O, Jia J, Childs EJ, Hoskins J, Figlioli G, Mocchi E, Collins I, Chung CC, Hautman C, Arslan AA, Beane-Freeman L, Bracci PM, Buring J, Duell EJ, Gallinger S, Giles GG, Goodman GE, Goodman PJ, Kaminen A, Kolonel LN, Kulke MH, Malats N, Olson SH, Sesso HD, Visvanathan K, White E, Zheng W, Abnet CC, Albanes D, Andreotti G, Brais L, Bueno-de-Mesquita HB, Basso D, Berndt SI, Boutron-Ruault MC, Bijlsma MF, Brenner H, Burdette L, Campa D, Caporaso NE, Capurso G, Cavestro GM, Cotterchio M, Costello E, Elena J, Boggi U, Gaziano JM, Gazouli M, Giovannucci EL, Goggins M, Gross M, Haiman CA, Hassan M, Helzlsouer KJ, Hu N, Hunter DJ, Iskierka-Jażdżewska E, Jenab M, Kaaks R, Key TJ, Khaw KT, Klein EA, Kogevinas M, Krogh V, Kupcinskas J, Kurtz RC, Landi MT, Landi S, Le Marchand L, Mambrini A, Mannisto S, Milne RL, Neale RE, Oberg AL, Panico S, Patel AV, Peeters PH, Peters U, Pezzilli R, Porta M, Purdue M, Quiros JR, Riboli E, Rothman N, Scarpa A, Scelo G, Shu XO, Silverman DT, Soucek P, Strobel O, Sund M, Malecka-Panas E, Taylor PR, Tavano F, Travis RC, Thornquist M, Tjønneland A, Tobias GS, Trichopoulos D, Vashist Y, Vodicka P, Wactawski-Wende J, Wentzensen N, Yu H, Yu K, Zeleniuch-Jacquotte A, Kooperberg C, Risch HA, Jacobs EJ, Li D, Fuchs C, Hoover R, Hartge P, Chanock SJ, Petersen GM, Stolzenberg-Solomon RS, Wolpin BM, Kraft P, Klein AP, Canzian F, Amundadottir LT. *Oncotarget.* 2016 Oct 11;7(41):66328-66343. doi: 10.18632/oncotarget.11041. PMID: 27579533 Free PMC Article
32. Environmental risk factors for pancreatic cancer: an update. Barone E, Corrado A, Gemignani F, Landi S. *Arch Toxicol.* 2016 Nov;90(11):2617-2642. Epub 2016 Aug 18. Review. PMID: 27538405
33. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Campa D, Pastore M, Gentiluomo M, Talar-Wojnarowska R, Kupcinskas J, Malecka-Panas E, Neoptolemos JP, Niesen W, Vodicka P, Delle Fave G, Bueno-de-Mesquita HB, Gazouli M, Pacetti P, Di Leo M, Ito H, Klüter H, Soucek P, Corbo V, Yamao K, Hosono S, Kaaks R, Vashist Y, Gioffreda D, Strobel O, Shimizu Y, Dijk F, Andriulli A, Ivanauskas A, Bugert P, Tavano F, Vodickova L, Zamboni CF, Lovecek M, Landi S, Key TJ, Boggi U, Pezzilli R, Jamrozik K, Mohelnikova-Duchonova B, Mambrini A, Bambi F, Busch O, Paziienza V, Valente R, Theodoropoulos GE, Hackert T, Capurso G, Cavestro GM, Pasquali C, Basso D, Sperti C, Matsuo K, Büchler M, Khaw KT, Izbicki J, Costello E, Katzke V, Michalski C, Stępień A, Rizzato C, Canzian F. *Oncotarget.* 2016 Aug 30;7(35):57011-57020. doi: 10.18632/oncotarget.10935. PMID: 27486979 Free PMC Article

34. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis. Ríos-Tamayo R, Lupiáñez CB, Campa D, Hielscher T, Weinhold N, Martínez-López J, Jerez A, Landi S, Jamroziak K, Dumontet C, Wątek M, Lesueur F, Reis RM, Marques H, Jurczynszyn A, Vogel U, Buda G, García-Sanz R, Orciuolo E, Petrini M, Vangsted AJ, Gemignani F, Försti A, Goldschmidt H, Hemminki K, Canzian F, Jurado M, Sainz J. *Oncotarget*. 2016 Sep 13;7(37):59029-59048. doi: 10.18632/oncotarget.10665. PMID: 27437873 Free PMC Article
35. Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma. Cipollini M, Figlioli G, Maccari G, Garritano S, De Santi C, Melaiu O, Barone E, Bambi F, Ermini S, Pellegrini G, Cristaudo A, Foddìs R, Bonotti A, Romei C, Vivaldi A, Agate L, Molinari E, Barale R, Forsti A, Hemminki K, Elisei R, Gemignani F, Landi S. *DNA Repair (Amst)*. 2016 May;41:27-31. doi: 10.1016/j.dnarep.2016.03.011. Epub 2016 Mar 31. PMID: 27062014
36. The importance of p53 pathway genetics in inherited and somatic cancer genomes. Stracquadanio G, Wang X, Wallace MD, Grawenda AM, Zhang P, Hewitt J, Zeron-Medina J, Castro-Giner F, Tomlinson IP, Goding CR, Cygan KJ, Fairbrother WG, Thomas LF, Sætrom P, Gemignani F, Landi S, Schuster-Böckler B, Bell DA, Bond GL. *Nat Rev Cancer*. 2016 Apr;16(4):251-65. doi: 10.1038/nrc.2016.15. Review. PMID: 27009395
37. Runs of homozygosity and inbreeding in thyroid cancer. Thomsen H, Chen B, Figlioli G, Elisei R, Romei C, Cipollini M, Cristaudo A, Bambi F, Hoffmann P, Herms S, Landi S, Hemminki K, Gemignani F, Försti A. *BMC Cancer*. 2016 Mar 16;16:227. doi: 10.1186/s12885-016-2264-7. PMID: 26984635 Free PMC Article
38. Targeting hypoxic response for cancer therapy. Paolicchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, Mutti L, Landi S. *Oncotarget*. 2016 Mar 22;7(12):13464-78. doi: 10.18632/oncotarget.7229. Review. PMID: 26859576 Free PMC Article
39. A Comprehensive Meta-analysis of Case-Control Association Studies to Evaluate Polymorphisms Associated with the Risk of Differentiated Thyroid Carcinoma. Figlioli G, Elisei R, Romei C, Melaiu O, Cipollini M, Bambi F, Chen B, Köhler A, Cristaudo A, Hemminki K, Gemignani F, Försti A, Landi S. *Cancer Epidemiol Biomarkers Prev*. 2016 Apr;25(4):700-13. doi: 10.1158/1055-9965.EPI-15-0652. Epub 2016 Feb 3. PMID: 26843521 Free Article
40. Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma. Pellé L, Cipollini M, Tremmel R, Romei C, Figlioli G, Gemignani F, Melaiu O, De Santi C, Barone E, Elisei R, Seiser E, Innocenti F, Zanger UM, Landi S. *Arch Toxicol*. 2016 Dec;90(12):3099-3109. Epub 2016 Jan 19. PMID: 26783003
41. Double-strand break repair and colorectal cancer: gene variants within 3' UTRs and microRNAs binding as modulators of cancer risk and clinical outcome. Naccarati A, Rosa F, Vymetalkova V, Barone E, Jiraskova K, Di Gaetano C, Novotny J, Levy M, Vodickova L, Gemignani F, Buchler T, Landi S, Vodicka P, Pardini B. *Oncotarget*. 2016 Apr 26;7(17):23156-69. doi: 10.18632/oncotarget.6804. PMID: 26735576 Free PMC Article
42. Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. Ríos R, Lupiáñez CB, Campa D, Martino A, Martínez-López J, Martínez-Bueno M, Varkonyi J, García-Sanz R, Jamroziak K, Dumontet C, Cayuela AJ, Wątek M, Landi S, Rossi AM, Lesueur F, Reis RM, Moreno V, Marques H, Jurczynszyn A, Andersen V, Vogel U, Buda G, Orciuolo E, Jacobsen SE, Petrini M, Vangsted AJ, Gemignani F, Canzian F, Jurado M, Sainz J. *Endocr Relat Cancer*. 2015 Aug;22(4):545-59. doi: 10.1530/ERC-15-0029. Epub 2015 Jun 22. PMID: 26099684
43. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Childs EJ, Mocchi E, Campa D, Bracci PM, Gallinger S, Goggins M, Li D, Neale RE, Olson SH, Scelo G, Amundadottir LT, Bamlet WR, Bijlsma MF, Blackford A, Borges M, Brennan P, Brenner H, Bueno-de-Mesquita HB, Canzian F, Capurso G, Cavestro GM, Chaffee KG, Chanock SJ, Cleary SP, Cotterchio M, Foretova L, Fuchs C, Funel N, Gazouli M, Hassan M, Herman JM, Holcatova I, Holly EA, Hoover RN, Hung RJ, Janout V, Key TJ, Kupcinskas J, Kurtz RC, Landi S, Lu L, Malecka-Panas E, Mambrini A, Mohelnikova-Duchonova B, Neoptolemos JP, Oberg AL, Orlov I, Pasquali C, Pezzilli R, Rizzato C, Saldia A, Scarpa A, Stolzenberg-Solomon RZ, Strobel O, Tavano F, Vashisth YK, Vodicka P, Wolpin BM, Yu H, Petersen GM, Risch HA, Klein AP. *Nat Genet*. 2015 Aug;47(8):911-6. doi: 10.1038/ng.3341. Epub 2015 Jun 22. PMID: 26098869 Free PMC Article
44. Campa D, Rizzato C, Stolzenberg-Solomon R, Pacetti P, Vodicka P, Cleary SP, Capurso G, Bueno-de-Mesquita HB, Werner J, Gazouli M, Butterbach K, Ivanauskas A, Giese N, Petersen GM, Fogar P, Wang Z, Bassi C, Ryska M, Theodoropoulos GE, Kooperberg C, Li D, Greenhalf W, Pasquali C, Hackert T, Fuchs CS, Mohelnikova-Duchonova B, Sperti C, Funel N, Dieffenbach AK, Wareham NJ, Buring J, Holcátová I, Costello E, Zambon CF, Kupcinskas J, Risch HA, Kraft P, Bracci PM, Pezzilli R, Olson SH, Sesso HD, Hartge P, Strobel O, Malecka-Panas E, Visvanathan K, Arslan AA, Pedrazzoli S, Souček P, Gioffreda D, Key TJ, Talar-Wojnarowska R, Scarpa A, Mambrini A, Jacobs EJ, Jamroziak K, Klein A, Tavano F, Bambi F, **Landi S**, Austin MA, Vodickova L, Brenner H, Chanock SJ, Delle Fave G, Piepoli A, Cantore M, Zheng W, Wolpin BM, Amundadottir LT, Canzian F. The TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. *Int J Cancer*. 2015 May 4. doi: 10.1002/ijc.29590. [Epub ahead of print] PubMed PMID: 25940397.
45. Melaiu O, Melissari E, Mutti L, Bracci E, De Santi C, Iofrida C, Di Russo M, Cristaudo A, Bonotti A, Cipollini M, Garritano SI, Foddìs R, Lucchi M, Pellegrini S, Gemignani F, **Landi S**. Expression status of candidate genes in mesothelioma tissues and cell lines. *Mutat Res*. 2015 Jan;771:6-12. doi:10.1016/j.mrfmmm.2014.11.002. Epub 2014 Nov 13. PubMed PMID: 25771974.
46. Figlioli G, Chen B, Elisei R, Romei C, Campo C, Cipollini M, Cristaudo A, Bambi F, Paolicchi E, Hoffmann P, Herms S, Kalembe M, Kula D, Pastor S, Marcos R, Velázquez A, Jarzemb B, **Landi S**, Hemminki K, Gemignani F, Forsti A. Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk. *Sci Rep*. 2015 Mar 10;5:8922. doi: 10.1038/srep08922. PubMed PMID: 25753578; PubMed Central PMCID: PMC4354074.
47. Zamora-Ros R, Shivappa N, Steck SE, Canzian F, **Landi S**, Alonso MH, Herbert JR, Moreno V. Dietary inflammatory index and

inflammatory gene interactions in relation to colorectal cancer risk in the Bellvitge colorectal cancer case-control study. *Genes Nutr.* 2015 Jan;10(1):447. doi:10.1007/s12263-014-0447-x. Epub 2014 Dec 9. PubMed PMID: 25488145; PubMed Central PMCID: PMC4259879.

48. Garritano S, De Santi C, Silvestri R, Melaiu O, Cipollini M, Barone E, Lucchi M, Barale R, Mutti L, Gemignani F, Bonotti A, Foddis R, Cristaudo A, **Landi S**. A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people. *J Thorac Oncol.* 2014 Nov;9(11):1662-8. doi: 10.1097/JTO.0000000000000322. PubMed PMID: 25436799.
49. Cipollini M, **Landi S**, Gemignani F. MicroRNA binding site polymorphisms as biomarkers in cancer management and research. *Pharmacogenomics Pers Med.* 2014 Jul;7:173-91. doi: 10.2147/PGPM.S61693. eCollection 2014. Review. PubMed PMID:25114582; PubMed Central PMCID: PMC4126202.
50. Campa D, Martino A, Varkonyi J, Lesueur F, Jamrozak K, **Landi S**, Jurczynski A, Marques H, Andersen V, Jurado M, Brenner H, Petrini M, Vogel U, Garcia-Sanz R, Buda G, Gemignani F, Rios R, Vangsted AJ, Dumontet C, Martinez-Lopez J, Moreno MJ, St?pie? A, W?tek M, Moreno V, Dieffenbach AK, Rossi AM, Butterbach K, Jacobsen SE, Goldschmidt H, Sainz J, Hillengass J, Orciuolo E, Dudzi?ski M, Weinhold N, Reis RM, Canzian F. Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. *Int J Cancer.* 2015 Mar;136(5):E351-8. doi: 10.1002/ijc.29101. Epub 2014 Aug 6. PubMed PMID: 25066524.
51. Figlioli G, K?hler A, Chen B, Elisei R, Romei C, Cipollini M, Cristaudo A, Bambi F, Paolicchi E, Hoffmann P, Herms S, Kalemba M, Kula D, Pastor S, Marcos R, Vel zquez A, Jarz?b B, **Landi S**, Hemminki K, F?rsti A, Gemignani F. Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. *J Clin Endocrinol Metab.* 2014 Oct;99(10):E2084-92. doi:10.1210/jc.2014-1734. Epub 2014 Jul 16. PubMed PMID: 25029422.
52. Xu L, Port M, **Landi S**, Gemignani F, Cipollini M, Elisei R, Goudeva L, M?ller JA, Nerlich K, Pellegrini G, Reiners C, Romei C, Schwab R, Abend M, Sturgis EM. Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies. *Thyroid.* 2014 Jun;24(6):966-74. doi: 10.1089/thy.2013.0566. Epub 2014 May 5. PubMed PMID: 24555500; PubMed Central PMCID: PMC4046192.
53. Martino A, Campa D, Jurczynski A, Martinez-Lopez J, Moreno MJ, Varkonyi J, Dumontet C, Garcia-Sanz R, Gemignani F, Jamrozak K, St?pie? A, Jacobsen SE, Andersen V, Jurado M, **Landi S**, Rossi AM, Lesueur F, Marques H, Dudzi?ski M, W?tek M, Moreno V, Orciuolo E, Petrini M, Reis RM, Rios R, Sainz J, Vogel U, Buda G, Vangsted AJ, Canzian F. Genetic variants and multiple myeloma risk: IMMENSE validation of the best reported associations--an extensive replication of the associations from the candidate gene era. *Cancer Epidemiol Biomarkers Prev.* 2014 Apr;23(4):670-4. doi: 10.1158/1055-9965.EPI-13-1115. Epub 2014 Feb 12. PubMed PMID: 24521996.
54. Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Mutti L, Barale R, Gemignani F, Giamas G, **Landi S**. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma. *PLoS One.* 2014 Jan 21;9(1):e85935. doi:10.1371/journal.pone.0085935. eCollection 2014. PubMed PMID: 24465798; PubMed Central PMCID: PMC3897543.
55. Pardini B, Rosa F, Barone E, Di Gaetano C, Slyskova J, Novotny J, Levy M, Garritano S, Vodickova L, Buchler T, Gemignani F, **Landi S**, Vodicka P, Naccarati A. Variation within 3'-UTRs of base excision repair genes and response to therapy in colorectal cancer patients: A potential modulation of microRNAs binding. *Clin Cancer Res.* 2013 Nov 1;19(21):6044-56. doi: 10.1158/1078-0432.CCR-13-0314. Epub 2013 Sep 13. PubMed PMID: 24036853.
56. Cipollini M, Figlioli G, Garritano S, Bramante S, Maiorano L, Gnudi F, Cecchini A, De Paola F, Damici L, Frixia T, **Landi D**, Cancemi L, De Santi C, Melaiu O, Foddis R, Cristaudo A, Bonotti A, Romei C, Elisei R, Pellegrini G, Barale R, Gemignani F, **Landi S**. Risk of differentiated thyroid carcinoma and polymorphisms within the susceptibility cancer region 8q24. *Cancer Epidemiol Biomarkers Prev.* 2013 Nov;22(11):2121-5. doi: 10.1158/1055-9965.EPI-13-0790. Epub 2013 Sep 5. PubMed PMID: 24008490.
57. K?hler A, Chen B, Gemignani F, Elisei R, Romei C, Figlioli G, Cipollini M, Cristaudo A, Bambi F, Hoffmann P, Herms S, Kalemba M, Kula D, Harris S, Broderick P, Houlston R, Pastor S, Marcos R, Vel zquez A, Jarzab B, Hemminki K, **Landi S**, F?rsti A. Genome-wide association study on differentiated thyroid cancer. *J Clin Endocrinol Metab.* 2013 Oct;98(10):E1674-81. doi: 10.1210/jc.2013-1941. Epub 2013 Jul 26. PubMed PMID: 23894154.
58. Garritano S, Inga A, Gemignani F, **Landi S**. More targets, more pathways and more clues for mutant p53. *Oncogenesis.* 2013 Jul 1;2:e54. doi:10.1038/oncsis.2013.15. PubMed PMID: 23817466; PubMed Central PMCID: PMC3740285.
59. Cipollini M, Pastor S, Gemignani F, Castell J, Garritano S, Bonotti A, Biarn?s J, Figlioli G, Romei C, Marcos R, Cristaudo A, Elisei R, **Landi S**, Vel zquez A. TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. *Int J Cancer.* 2013 Dec 15;133(12):2843-51. doi:10.1002/ijc.28317. Epub 2013 Jul 13. PubMed PMID: 23754668.
60. Melaiu O, Facioni MS, Cabiati M, Caruso R, Giannesi D, **Landi S**, Gemignani F, Del Ry S. Characterization of novel 3'untranslated regions and related polymorphisms of the gene NPPC, encoding for the C-type natriuretic peptide. *Peptides.* 2013 Jun;44:93-9. doi: 10.1016/j.peptides.2013.03.012. Epub 2013 Mar 28. PubMed PMID: 23542429.
61. Bonotti A, Foddis R, Papa A, Bigotti M, de Santi C, Gemignani F, **Landi S**, Cristaudo A. [Identification and characterization of microRNA involving in malignant pleural mesothelioma]. *G Ital Med Lav Ergon.* 2012 Jul-Sep;34(3Suppl):552-4. Italian. PubMed PMID: 23405713.

62. Rizzato C, Campa D, Pezzilli R, Soucek P, Greenhalf W, Capurso G, Talar-Wojnarowska R, Heller A, Jamrozik K, Khaw KT, Key TJ, Bambi F, **Landi S**, Mohelnikova-Duchonova B, Vodickova L, B• chler MW, Bugert P, Vodicka P, Neoptolemos JP, Werner J, Hoheisel JD, Bauer AS, Giese N, Canzian F. ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. *Oncol Rep.* 2013 Apr;29(4):1637-44. doi:10.3892/or.2013.2285. Epub 2013 Feb 12. PubMed PMID: 23403949.
63. Martino A, Sainz J, Manuel Reis R, Moreno V, Buda G, Lesueur F, Marques H, Garcia-Sanz R, Rjos R, Stein A, Dumontet C, Gemignani F, Maria Rossi A, **Landi S**, Jurado M, Petrini M, Jamrozik K, Campa D, Canzian F. Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMEnSE consortium. *J Hum Genet.* 2013 Mar;58(3):155-9. doi: 10.1038/jhg.2012.149. Epub 2013 Jan 10. PubMed PMID: 23303387.
64. Tavanti A, **Landi S**, Senesi S. APEX DNA microarray for the identification of pathogenic fungi. *Methods Mol Biol.* 2013;968:63-70. doi:10.1007/978-1-62703-257-5_4. PubMed PMID: 23296885.
65. Campa D, Rizzato C, Bauer AS, Werner J, Capurso G, Costello E, Talar-Wojnarowska R, Jamrozik K, Pezzilli R, Gazouli M, Khaw KT, Key TJ, Bambi F, Mohelnikova-Duchonova B, Heller A, **Landi S**, Vodickova L, Theodoropoulos G, Bugert P, Vodicka P, Hoheisel JD, Delle Fave G, Neoptolemos JP, Soucek P, B• chler MW, Giese N, Canzian F. Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations. *Cancer Epidemiol Biomarkers Prev.* 2013 Feb;22(2):320-3. doi: 10.1158/1055-9965.EPI-12-1182. Epub 2012 Dec 18. PubMed PMID: 23250936.
66. Campa D, Rizzato C, Capurso G, Giese N, Funel N, Greenhalf W, Soucek P, Gazouli M, Pezzilli R, Pasquali C, Talar-Wojnarowska R, Cantore M, Andriulli A, Scarpa A, Jamrozik K, Delle Fave G, Costello E, Khaw KT, Heller A, Key TJ, Theodoropoulos G, Malecka-Panas E, Mambrini A, Bambi F, **Landi S**, Pedrazzoli S, Bassi C, Pacetti P, Piepoli A, Tavano F, di Sebastiano P, Vodickova L, Basso D, Plebani M, Fogar P, B• chler MW, Bugert P, Vodicka P, Boggi U, Neoptolemos JP, Werner J, Canzian F. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. *Dig Liver Dis.* 2013 Feb;45(2):95-9. doi: 10.1016/j.dld.2012.09.014. Epub 2012 Dec 1. PubMed PMID: 23206934.
67. Figlioli G, **Landi S**, Romei C, Elisei R, Gemignani F. Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. *Mutat Res.* 2013 Jan-Mar;752(1):36-44. doi: 10.1016/j.mrrev.2012.09.002. Epub 2012 Oct 8. Review. PubMed PMID: 23059849.
68. Martino A, Campa D, Jamrozik K, Reis RM, Sainz J, Buda G, Garcia-Sanz R, Lesueur F, Marques H, Moreno V, Jurado M, Rjos R, Szemraj-Rogucka Z, Szemraj J, Tjnneland A, Overvad K, Vangsted AJ, Vogel U, Mikala G, K d r K, Szombath G, Varkonyi J, Orciuolo E, Dumontet C, Gemignani F, Rossi AM, **Landi S**, Petrini M, Houlston RS, Hemminki K, Canzian F. Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. *Br J Haematol.* 2012 Sep;158(6):805-9. doi: 10.1111/j.1365-2141.2012.09244.x. Epub 2012 Jul 24. PubMed PMID: 22823248.
69. Campa D, Martino A, Sainz J, Buda G, Jamrozik K, Weinhold N, Vieira Reis RM, Garcia-Sanz R, Jurado M, Rjos R, Szemraj-Rogucka Z, Marques H, Lesueur F, Bugert P, Moreno V, Szemraj J, Orciuolo E, Gemignani F, Rossi AM, Dumontet C, Petrini M, Goldschmidt H, **Landi S**, Canzian F. Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium. *Br J Haematol.* 2012 May;157(3):331-8. Epub 2012 Feb 13. PubMed PMID: 22590720.
70. Di Cianni F, Campa D, Tallaro F, Rizzato C, De Rango F, Barale R, Passarino G, Canzian F, Gemignani F, Montesanto A, **Landi S**, Rose G. MAP3K7 and GSTZ1 are associated with human longevity: a two-stage case-control study using a multilocus genotyping. *Age (Dordr).* 2013 Aug;35(4):1357-66. doi:10.1007/s11357-012-9416-8. Epub 2012 May 11. PubMed PMID: 22576335; PubMed Central PMCID: PMC3705096.
71. **Landi D**, Gemignani F, **Landi S**. Role of variations within microRNA-binding sites in cancer. *Mutagenesis.* 2012 Mar;27(2):205-10. doi: 10.1093/mutage/ger055. PubMed PMID: 22294768.
72. **Landi D**, Gemignani F, Pardini B, Naccarati A, Garritano S, Vodicka P, Vodickova L, Canzian F, Novotny J, Barale R, **Landi S**. Identification of candidate genes carrying polymorphisms associated with the risk of colorectal cancer by analyzing the colorectal mutome and microRNAome. *Cancer.* 2012 Oct 1;118(19):4670-80. doi: 10.1002/cncr.27435. Epub 2012 Jan 26. PubMed PMID: 22282400.
73. Melaiu O, Cristaudo A, Melissari E, Di Russo M, Bonotti A, Bruno R, Foddìs R, Gemignani F, Pellegrini S, **Landi S**. A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma. *Mutat Res.* 2012 Apr-Jun;750(2):132-40. doi:10.1016/j.mrrev.2011.12.003. Epub 2011 Dec 15. Review. PubMed PMID: 22198210.
74. Martino A, Campa D, Buda G, Sainz J, Garcia-Sanz R, Jamrozik K, Reis RM, Weinhold N, Jurado M, Rjos R, Szemraj-Rogucka Z, Marques H, Szemraj J, Stein A, Kumar R, Orciuolo E, Gemignani F, **Landi S**, Goldschmidt H, Petrini M, Dumontet C, Canzian F, Rossi AM. Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium. *Leukemia.* 2012 Jun;26(6):1419-22. doi: 10.1038/leu.2011.352. Epub 2011 Dec 20. Erratum in: *Leukemia.* 2013 Jul;27(7):1615-6. PubMed PMID: 22182917.
75. Teo MT, **Landi D**, Taylor CF, Elliott F, Vaslin L, Cox DG, Hall J, **Landi S**, Bishop DT, Kiltie AE. The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy

outcomes. *Carcinogenesis*. 2012 Mar;33(3):581-6. doi:10.1093/carcin/bgr300. Epub 2011 Dec 12. PubMed PMID: 22166496; PubMed CentralPMCID: PMC3291859.

76. Martino A, Sainz J, Buda G, Jamrozak K, Reis RM, Garcia-Sanz R, Jurado M, Rios R, Szemraj-Rogucka Z, Marques H, Lesueur F, Moreno V, Orciuolo E, Gemignani F, **Landi** S, Rossi AM, Dumontet C, Petrini M, Campa D, Canzian F. Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMENSE consortium (review). *Int J Oncol*. 2012 Mar;40(3):625-38. doi:10.3892/ijo.2011.1284. Epub 2011 Dec 6. Review. PubMed PMID: 22159523.
77. Cosci B, Vivaldi A, Romei C, Gemignani F, **Landi** S, Ciampi R, Tacito A, Molinaro E, Agate L, Bottici V, Cappagli V, Viola D, Piaggi P, Vitti P, Pinchera A, Elisei R. In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. *Endocr Relat Cancer*. 2011 Sep 20;18(5):603-12. doi: 10.1530/ERC-11-0117. Print 2011 Oct. PubMed PMID:21810974.
78. Cristaudo A, Foddìs R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Bruno R, Gemignani F, **Landi** S. Two novel polymorphisms in 5' flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels. *Int J Biol Markers*. 2011 Apr-Jun;26(2):117-23. doi:10.5301/IJBM.2011.8332. PubMed PMID: 21574151.
79. Cancemi L, Romei C, Bertocchi S, Tarrini G, Spitaleri I, Cipollini M, **Landi** D, Garritano S, Pellegrini G, Cristaudo A, Pinchera A, Barale R, Elisei R, **Landi** S, Gemignani F. Evidence that the polymorphism Pro-282-Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma. *Int J Cancer*. 2011 Dec 15;129(12):2816-24. doi: 10.1002/ijc.25937. Epub 2011 Apr 25. PubMed PMID: 21520031.
80. **Landi** D, Moreno V, Guino E, Vodicka P, Pardini B, Naccarati A, Canzian F, Barale R, Gemignani F, **Landi** S. Polymorphisms affecting micro-RNA regulation and associated with the risk of dietary-related cancers: a review from the literature and new evidence for a functional role of rs17281995 (CD86) and rs1051690 (INSR), previously associated with colorectal cancer. *Mutat Res*. 2011 Dec 1;717(1-2):109-15. doi: 10.1016/j.mrfmmm.2010.10.002. Epub 2010 Oct 30. Review. PubMed PMID: 20971123.
81. **Landi** D, Barale R, Gemignani F, **Landi** S. Prediction of the biological effect of polymorphisms within microRNA binding sites. *Methods Mol Biol*. 2011;676:197-210. doi: 10.1007/978-1-60761-863-8_14. PubMed PMID: 20931399.
82. Maccari G, Gemignani F, **Landi** S. COMPASS (COMplex PAttern of Sequence Search Software), a simple and effective tool for mining complex motifs in whole genomes. *Bioinformatics*. 2010 Jul 15;26(14):1777-8. doi:10.1093/bioinformatics/btq258. Epub 2010 May 25. PubMed PMID: 20501554.
83. Bellini I, Pitto L, Marini MG, Porcu L, Moi P, Garritano S, Boldrini L, Rainaldi G, Fontanini G, Chiarugi M, Barale R, Gemignani F, **Landi** S. DeltaN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region. *Hum Mutat*. 2010 Apr;31(4):456-65. doi: 10.1002/humu.21214. PubMed PMID: 20127977.
84. Dumontet C, **Landi** S, Reiman T, Perry T, Plesa A, Bellini I, Barale R, Pilarski LM, Troncy J, Tavtigian S, Gemignani F. Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan. *Bone Marrow Transplant*. 2010 Aug;45(8):1316-24. doi: 10.1038/bmt.2009.335. Epub 2009 Dec 7. PubMed PMID: 19966851.
85. Gao Y, He Y, Ding J, Wu K, Hu B, Liu Y, Wu Y, Guo B, Shen Y, **Landi** D, **Landi** S, Zhou Y, Liu H. An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3' untranslated region confers risk for hepatocellular carcinoma. *Carcinogenesis*. 2009 Dec;30(12):2064-9. doi: 10.1093/carcin/bgp283. Epub . PubMed PMID: 19917630.
86. Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, Le Calvez-Kelm F, Brugeres L, Vargas FR, Brentani RR, Ashton-Prolla P, **Landi** S, Tavtigian SV, Hainaut P, Achatz MI. Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. *Hum Mutat*. 2010 Feb;31(2):143-50. doi: 10.1002/humu.21151. PubMed PMID: 19877175.
87. Cristaudo A, Foddìs R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Bruno R, **Landi** D, Gemignani F, **Landi** S. Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein. *Occup Environ Med*. 2010 Apr;67(4):233-6. doi: 10.1136/oem.2009.049205. Epub 2009 Oct 26. PubMed PMID: 19858537.
88. Gemignani F, Neri M, Bottari F, Barale R, Canessa PA, Canzian F, Ceppi M, Spitaleri I, Cipollini M, Ivaldi GP, Mencoboni M, Scaruffi P, Tonini GP, Ugolini D, Mutti L, Bonassi S, **Landi** S. Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism. *Mutat Res*. 2009 Dec 1;671(1-2):76-83. doi:10.1016/j.mrfmmm.2009.09.003. Epub 2009 Sep 12. PubMed PMID: 19751749.
89. Costa B, Pini S, Martini C, Abelli M, Gabelloni P, **Landi** S, Muti M, Gesi C, Lari L, Cardini A, Galderisi S, Mucci A, Lucacchini A, Cassano GB. Ala147Thr substitution in translocator protein is associated with adult separation anxiety in patients with depression. *Psychiatr Genet*. 2009 Apr;19(2):110-1. doi:10.1097/YPG.0b013e32832080f6. PubMed PMID: 19668118.
90. Armani C, **Landi** S, Nuti M, Di Stefano R, Balbarini A. HAS-1 genetic polymorphism in sporadic abdominal aortic aneurysm. *Heart Int*. 2009 Jun 30;4(1):e1. doi: 10.4081/hi.2009.e1. PubMed PMID: 21977277; PubMed Central PMCID: PMC3184700.
91. Lagani V, Montesanto A, Di Cianni F, Moreno V, **Landi** S, Conforti D, Rose G, Passarino G. A novel similarity-measure for the analysis of genetic data in complex phenotypes. *BMC Bioinformatics*. 2009 Jun 16;10 Suppl 6:S24. doi:10.1186/1471-2105-10-S6-S24. PubMed PMID: 19534750; PubMed Central PMCID: PMC2697648.

92. Costa B, Pini S, Gabelloni P, Abelli M, Lari L, Cardini A, Muti M, Gesi C, **Landi** S, Galderisi S, Mucci A, Lucacchini A, Cassano GB, Martini C. Oxytocin receptor polymorphisms and adult attachment style in patients with depression. *Psychoneuroendocrinology*. 2009 Nov;34(10):1506-14. doi:10.1016/j.psyneuen.2009.05.006. Epub 2009 Jun 9. PubMed PMID: 19515497.
93. Pardini B, Naccarati A, Polakova V, Smerhovsky Z, Hlavata I, Soucek P, Novotny J, Vodickova L, Tomanova V, **Landi** S, Vodicka P. NBN 657del5 heterozygous mutations and colorectal cancer risk in the Czech Republic. *Mutat Res*. 2009 Jun;666(1-2):64-7. doi: 10.1016/j.mrfmmm.2009.04.004. Epub 2009 Apr 22. PubMed PMID: 19393249.
94. Polakova V, Pardini B, Naccarati A, **Landi** S, Slyskova J, Novotny J, Vodickova L, Bermejo JL, Hanova M, Smerhovsky Z, Tulupova E, Kumar R, Hemminki K, Vodicka P. Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic. *Hum Mutat*. 2009 Apr;30(4):661-8. doi:10.1002/humu.20931. PubMed PMID: 19224585.
95. Garritano S, Gemignani F, Voegelé C, Nguyen-Dumont T, Le Calvez-Kelm F, DeSilva D, Lesueur F, **Landi** S, Tavtigian SV. Determining the effectiveness of High Resolution Melting analysis for SNP genotyping and mutation scanning at the TP53 locus. *BMC Genet*. 2009 Feb 17;10:5. doi: 10.1186/1471-2156-10-5. PubMed PMID:19222838; PubMed Central PMCID: PMC2648999.
96. **Landi** S. Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature. *Mutat Res*. 2009 Mar-Jun;681(2-3):299-307. doi: 10.1016/j.mrrev.2008.12.001. Epub 2008 Dec 27. Review. PubMed PMID:19150414.
97. Betti M, Neri M, Ferrante D, **Landi** S, Biava A, Gemignani F, Bertolotti M, Mirabelli D, Padoan M, Ugolini D, Botta M, Bonassi S, Magnani C, Dianzani I. Pooled analysis of NAT2 genotypes as risk factors for asbestos-related malignant mesothelioma. *Int J Hyg Environ Health*. 2009 May;212(3):322-9. doi:10.1016/j.ijheh.2008.08.001. Epub 2008 Oct 1. PubMed PMID: 18838334.
98. Neri M, Ugolini D, Dianzani I, Gemignani F, **Landi** S, Cesario A, Magnani C, Mutti L, Puntoni R, Bonassi S. Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases. *Mutat Res*. 2008 Jul-Aug;659(1-2):126-36. doi: 10.1016/j.mrrev.2008.02.002. Epub 2008 Feb 23. Review. PubMed PMID: 18420450.
99. **Landi** D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, Novotny J, Fosti A, Hemminki K, Canzian F, **Landi** S. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. *Carcinogenesis*. 2008 Mar;29(3):579-84. doi: 10.1093/carcin/bgm304. Epub 2008 Jan 12. PubMed PMID:18192692.
100. Campa D, Tavanti A, Gemignani F, Mogavero CS, Bellini I, Bottari F, Barale R, **Landi** S, Senesi S. DNA microarray based on arrayed-primer extension technique for identification of pathogenic fungi responsible for invasive and superficial mycoses. *J Clin Microbiol*. 2008 Mar;46(3):909-15. Epub 2007 Dec 26. PubMed PMID: 18160452; PubMed Central PMCID: PMC2268329.
101. **Landi** D, Gemignani F, Barale R, **Landi** S. A catalog of polymorphisms falling in microRNA-binding regions of cancer genes. *DNA Cell Biol*. 2008 Jan;27(1):35-43. PubMed PMID: 17941804.
102. Ugolini D, Neri M, Ceppi M, Cesario A, Dianzani I, Filiberti R, Gemignani F, **Landi** S, Magnani C, Mutti L, Puntoni R, Bonassi S. Genetic susceptibility to malignant mesothelioma and exposure to asbestos: the influence of the familial factor. *Mutat Res*. 2008 Mar-Apr;658(3):162-71. Epub 2007 Aug 10. Review. PubMed PMID: 17904414.
103. Gheit T, Billoud G, de Koning MN, Gemignani F, Forslund O, Sylla BS, Vaccarella S, Franceschi S, **Landi** S, Quint WG, Canzian F, Tommasino M. Development of a sensitive and specific multiplex PCR method combined with DNA microarray primer extension to detect Betapapillomavirus types. *J Clin Microbiol*. 2007 Aug;45(8):2537-44. Epub 2007 Jun 20. PubMed PMID: 17581938; PubMed Central PMCID: PMC1951219.
104. Bottari F, **Landi** S, Gemignani F. Single tube genotyping of GSTM1, GSTT1 and TP53 polymorphisms by multiplex PCR. *DNA Seq*. 2006 Oct;17(5):396-9. PubMed PMID: 17343214.
105. **Landi** S, Gemignani F, Neri M, Barale R, Bonassi S, Bottari F, Canessa PA, Canzian F, Ceppi M, Filiberti R, Ivaldi GP, Mencoboni M, Scaruffi P, Tonini GP, Mutti L, Puntoni R. Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma. *Int J Cancer*. 2007 Jun 15;120(12):2739-43. PubMed PMID: 17290392.
106. Gemignani F, **Landi** S, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Gaborieau V, Gioia-Patricola L, Bellini I, Barale R, Canzian F, Hall J, Boffetta P, Hung RJ, Brennan P. Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. *Carcinogenesis*. 2007 Jun;28(6):1287-93. Epub 2007 Jan 27. PubMed PMID: 17259654.
107. **Landi** S, Bottari F, Gemignani F, Gioia-Patricola L, Guino E, Osorio A, de Oca J, Capella G, Canzian F, Moreno V, Bellvitge Colorectal Cancer Study Group. Interleukin-4 and interleukin-4 receptor polymorphisms and colorectal cancer risk. *Eur J Cancer*. 2007 Mar;43(4):762-8. Epub 2007 Jan 26. PubMed PMID:17258448.
108. **Landi** S, Gemignani F, Canzian F, Gaborieau V, Barale R, **Landi** D, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Gioia-Patricola L, Hall J, Boffetta P, Hung RJ, Brennan P. DNA repair and cell cycle control genes and the risk of young-onset lung cancer. *Cancer Res*. 2006 Nov 15;66(22):11062-9. PubMed PMID: 17108146.

109. **Landi S**, Gemignani F, Bottari F, Gioia-Patricola L, Guino E, Cambray M, Biondo S, Capella G, Boldrini L, Canzian F, Moreno V. Polymorphisms within inflammatory genes and colorectal cancer. *J Negat Results Biomed*. 2006 Oct 24;5:15. PubMed PMID: 17062130; PubMed Central PMCID: PMC1634873.
110. Hung RJ, Boffetta P, Canzian F, Moullan N, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Chabrier A, **Landi S**, Gemignani F, Hall J, Brennan P. Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case-control study in Central Europe. *Cancer Res*. 2006 Aug 15;66(16):8280-6. PubMed PMID: 16912209.
111. Gunter MJ, Canzian F, **Landi S**, Chanock SJ, Sinha R, Rothman N. Inflammation-related gene polymorphisms and colorectal adenoma. *Cancer Epidemiol Biomarkers Prev*. 2006 Jun;15(6):1126-31. PubMed PMID: 16775170.
112. Gheit T, **Landi S**, Gemignani F, Snijders PJ, Vaccarella S, Franceschi S, Canzian F, Tommasino M. Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. *J Clin Microbiol*. 2006 Jun;44(6):2025-31. PubMed PMID: 16757593; PubMed Central PMCID: PMC1489390.
113. Moreno V, Gemignani F, **Landi S**, Gioia-Patricola L, Chabrier A, Blanco I, Gonzalez S, Guino E, Capella G, Canzian F. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. *Clin Cancer Res*. 2006 Apr 1;12(7 Pt 1):2101-8. PubMed PMID: 16609022.
114. Stankov K, **Landi S**, Gioia-Patricola L, Bonora E, Volante M, Papotti M, Romeo G. GSTT1 and M1 polymorphisms in H₂O₂ rthle thyroid cancer patients. *Cancer Lett*. 2006 Aug 18;240(1):76-82. Epub 2006 Jan 20. PubMed PMID: 16427734.
115. Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Rinaldi S, **Landi S**, Boillot C, Monnier S, Chajšs V, Clavel-Chapelon F, T,hard B, Chang-Claude J, Linseisen J, Lahmann PH, Pischon T, Trichopoulos D, Trichopoulou A, Zilis D, Palli D, Tumino R, Vineis P, Berrino F, Bueno-de-Mesquita HB, van Gils CH, Peeters PH, Pera G, Ardanaz E, Chirlaque MD, Quirçs JR, Larraga N, Martínez-García C, Allen NE, Key TJ, Bingham SA, Khaw KT, Slimani N, Norat T, Riboli E, Kaaks R. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. *Br J Cancer*. 2006 Jan 30;94(2):299-307. PubMed PMID: 16404426; PubMed Central PMCID: PMC2361124.
116. Gemignani F, **Landi S**, Moreno V, Gioia-Patricola L, Chabrier A, Guino E, Navarro M, Cambray M, Capella G, Canzian F. Polymorphisms of the dopaminergic receptor gene DRD2 and colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2005 Jul;14(7):1633-8. PubMed PMID: 16030094.
117. **Landi S**, Gemignani F, Moreno V, Gioia-Patricola L, Chabrier A, Guino E, Navarro M, de Oca J, Capella G, Canzian F; Bellvitge Colorectal Cancer Study Group. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. *Pharmacogenet Genomics*. 2005 Aug;15(8):535-46. PubMed PMID: 16006997.
118. **Landi S**, Gemignani F, Monnier S, Canzian F. A database of single-nucleotide polymorphisms and a genotyping microarray for genetic epidemiology of lung cancer. *Exp Lung Res*. 2005 Mar;31(2):223-58. PubMed PMID: 15824023.
119. Gemignani F, **Landi S**, Chabrier A, Smet A, Zehbe I, Canzian F, Tommasino M. Generation of a DNA microarray for determination of E6 natural variants of human papillomavirus type 16. *J Virol Methods*. 2004 Aug;119(2):95-102. PubMed PMID: 15158590.
120. Bonassi S, Lando C, Ceppi M, **Landi S**, Rossi AM, Barale R. No association between increased levels of high-frequency sister chromatid exchange cells (HFCs) and the risk of cancer in healthy individuals. *Environ Mol Mutagen*. 2004;43(2):134-6. PubMed PMID: 14991754.
121. Gemignani F, Moreno V, **Landi S**, Moullan N, Chabrier A, Gutierrez-Enriquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. *Oncogene*. 2004 Mar 11;23(10):1954-6. PubMed PMID: 14647431.
122. **Landi S**, Gemignani F, Gioia-Patricola L, Chabrier A, Canzian F. Evaluation of a microarray for genotyping polymorphisms related to xenobiotic metabolism and DNA repair. *Biotechniques*. 2003 Oct;35(4):816-20, 822, 824-7. PubMed PMID: 14579748.
123. **Landi S**, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F; Bellvitge Colorectal Cancer Study Group. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFkB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. *Cancer Res*. 2003 Jul 1;63(13):3560-6. PubMed PMID: 12839942.
124. **Landi S**, Naccarati A, Ross MK, Hanley NM, Dailey L, Devlin RB, Vasquez M, Pegram RA, DeMarini DM. Induction of DNA strand breaks by trihalomethanes in primary human lung epithelial cells. *Mutat Res*. 2003 Jul 8;538(1-2):41-50. PubMed PMID: 12834753.
125. Naccarati A, Zanello A, **Landi S**, Consigli R, Migliore L. Sperm-FISH analysis and human monitoring: a study on workers occupationally exposed to styrene. *Mutat Res*. 2003 Jun 6;537(2):131-40. PubMed PMID: 12787818.

126. Gemignani F, Perra C, **Landi** S, Canzian F, Kurg A, Tänišson N, Galanello R, Cao A, Metspalu A, Romeo G. Reliable detection of beta-thalassemia and G6PD mutations by a DNA microarray. *Clin Chem*. 2002 Nov;48(11):2051-4. PubMed PMID:12406995.
127. Gemignani F, **Landi** S, Vivant F, Zienolddiny S, Brennan P, Canzian F. A catalogue of polymorphisms related to xenobiotic metabolism and cancer susceptibility. *Pharmacogenetics*. 2002 Aug;12(6):459-63. PubMed PMID: 12172214.
128. Gemignani F, **Landi** S, DeMarini DM, Kole R. Spontaneous and MNNG-induced reversion of an EGFP construct in HeLa cells: an assay for observing mutations in living cells by fluorescent microscopy. *Hum Mutat*. 2001 Dec;18(6):526-34. PubMed PMID: 11748845.
129. DeMarini DM, **Landi** S, Tian D, Hanley NM, Li X, Hu F, Roop BC, Mass MJ, Keohavong P, Gao W, Olivier M, Hainaut P, Mumford JL. Lung tumor KRAS and TP53 mutations in nonsmokers reflect exposure to PAH-rich coal combustion emissions. *Cancer Res*. 2001 Sep 15;61(18):6679-81. PubMed PMID: 11559534.
130. DeMarini DM, **Landi** S, Ohe T, Shaughnessy DT, Franz, n R, Richard AM. Mutation spectra in Salmonella of analogues of MX: implications of chemical structure for mutational mechanisms. *Mutat Res*. 2000 Sep 20;453(1):51-65. PubMed PMID:11006412.
131. **Landi** S, Iazzolino E, Barale R. Are baseline frequencies of SCEs, CAs, and MN in human lymphocytes related to hematological values? *Mutat Res*. 2000 Aug 21;469(1):159-66. PubMed PMID: 10946252.
132. Shaughnessy DT, Ohe T, **Landi** S, Warren SH, Richard AM, Munter T, Franz, n R, Kronberg L, DeMarini DM. Mutation spectra of the drinking water mutagen 3-chloro-4-methyl-5-hydroxy-2(5H)-furanone (MCF) in Salmonella TA100 and TA104: comparison to MX. *Environ Mol Mutagen*. 2000;35(2):106-13. PubMed PMID: 10712744.
133. **Landi** S, Barale R. Sister chromatid exchanges, chromosome aberrations and micronuclei in female lymphocytes: correlations with biological rhythms, miscarriages and contraceptive pill use. *Mutagenesis*. 1999 Nov;14(6):581-6. PubMed PMID: 10567033.
134. **Landi** S, Hanley NM, Kligerman AD, DeMarini DM. Induction of sister chromatid exchanges in human peripheral blood lymphocytes by bromoform: investigation of the role of GSTT1-1 polymorphism. *Mutat Res*. 1999 Oct 19;429(2):261-7. PubMed PMID: 10526210.
135. Ohe T, Shaughnessy DT, **Landi** S, Terao Y, Sawanishi H, Nukaya H, Wakabayashi K, DeMarini DM. Mutation spectra in Salmonella TA98, TA100, and TA104 of two phenylbenzotriazole mutagens (PBTA-1 and PBTA-2) detected in the Nishitakase River in Kyoto, Japan. *Mutat Res*. 1999 Oct 19;429(2):189-98. PubMed PMID:10526204.
136. **Landi** S, Frenzilli G, Milillo PC, Cocchi L, Sbrana I, Scapoli C, Barale R. Spontaneous sister chromatid exchange and chromosome aberration frequency in humans: the familial effect. *Mutat Res*. 1999 Aug 18;444(2):337-45. PubMed PMID:10521673.
137. **Landi** S, Hanley NM, Warren SH, Pegram RA, DeMarini DM. Induction of genetic damage in human lymphocytes and mutations in Salmonella by trihalomethanes: role of red blood cells and GSTT1-1 polymorphism. *Mutagenesis*. 1999 Sep;14(5):479-82. PubMed PMID: 10473651.
138. **Landi** S, Norppa H, Frenzilli G, Cipollini G, Ponzanelli I, Barale R, Hirvonen A. Individual sensitivity to cytogenetic effects of 1,2:3,4-diepoxybutane in cultured human lymphocytes: influence of glutathione S-transferase M1, P1 and T1 genotypes. *Pharmacogenetics*. 1998 Dec;8(6):461-71. PubMed PMID: 9918129.
139. Barale R, Chelotti L, Davini T, Del Ry S, Andreassi MG, Ballardini M, Bulleri M, He J, Baldacci S, Di Pede F, Gemignani F, **Landi** S. Sister chromatid exchange and micronucleus frequency in human lymphocytes of 1,650 subjects in an Italian population: II. Contribution of sex, age, and lifestyle. *Environ Mol Mutagen*. 1998;31(3):228-42. PubMed PMID: 9585261.
140. Barale R, Marrazzini A, Bacci E, Di Sibio A, Tessa A, Cocchi L, Scarcelli V, Lubrano V, Vassalle C, **Landi** S. Sister chromatid exchange and micronucleus frequency in human lymphocytes of 1,650 subjects in an Italian population: I. Contribution of methodological factors. *Environ Mol Mutagen*. 1998;31(3):218-27. PubMed PMID: 9585260.
141. Ponzanelli I, **Landi** S, Bernacchi F, Barale R. The nature of high frequency sister chromatid exchange cells (HFCs). *Mutagenesis*. 1997 Sep;12(5):329-33. PubMed PMID: 9379910.
142. **Landi** S, Ponzanelli I, Cipollini G, Frenzilli G, Luccini A, Milillo CP, Sbrana I, Barale R. Modulating factors of individual sensitivity to diepoxybutane: chromosome aberrations induced in vitro in human lymphocytes. *Mutagenesis*. 1997 Jan;12(1):17-22. PubMed PMID: 9025092.
143. **Landi** S, Frenzilli G, Sbrana I, Barale R. Modulating factors of individual sensitivity to diepoxybutane: sister chromatid exchanges induced in vitro in human lymphocytes. *Mutat Res*. 1996 Oct 25;357(1-2):75-82. PubMed PMID: 8876682.
144. **Landi** S, Ponzanelli I, Hirvonen A, Norppa H, Barale R. Repeated analysis of sister chromatid exchange induction by diepoxybutane in cultured human lymphocytes: effect of glutathione S-transferase T1 and M1 genotype. *Mutat Res*. 1996 Mar 26;351(1):79-85. PubMed PMID: 8602177.
145. Ponzanelli I, **Landi** S, Barale R. Persistence of 4-nitroquinoline-1-oxide induced lesions in human lymphocytes. *Mutat Res*. 1996 Feb 15;362(2):193-7. PubMed PMID: 8596538.

146. Landi S, Ponzanelli I, Barale R. Effect of red cells and plasma blood indeterming individual lymphocytes sensitivity to diepoxybutane assessed by invitro induced sister chromatid exchanges. Mutat Res. 1995 Nov;348(3):117-23.PubMed PMID: 8524363.
147. Ponzanelli I, Landi S, Barale R. Use of three-way differential staining and liquid holding for the assessment of individual repair capacity. Mutat Res. 1995 Feb;346(2):93-7. PubMed PMID: 7533894.
148. Sbrana I, Luccini A, Landi S, Barale R. Enhancement of SCE frequency byalpha-naphthoflavone in cultured lymphocytes in relation to environmental factors. Environ Mol Mutagen. 1995;26(4):331-7. PubMed PMID: 8575422.

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della L. 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 675/96 del 31/12/96.

Pisa, 09/02/2020

